Japan ophthalmic drugs drug class outlook (Revenue, USD million, 2021-2033)
- Anti-Allergy
- Anti-VEGF agents
- Anti-glaucoma
- Gene & Cell Therapy
- Others
- Anti-inflammatory
- Non-steroidal drugs
- Steroids
Japan ophthalmic drugs disease outlook (Revenue, USD million, 2021-2033)
- Dry Eye
- Gels
- Eye solutions & suspensions
- Capsules & Tablets
- Eye drops
- Ointments
- Allergies
- Gels
- Eye solutions & suspensions
- Capsules & Tablets
- Eye drops
- Ointments
- Glaucoma
- Gels
- Eye solutions & suspensions
- Capsules & Tablets
- Eye drops
- Ointments
- Infection
- Gels
- Eye solutions & suspensions
- Capsules & Tablets
- Eye drops
- Ointments
- Retinal Disorders
- Gels
- Eye solutions & suspensions
- Capsules & Tablets
- Eye drops
- Ointments
- Uveitis
- Gels
- Eye solutions & suspensions
- Capsules & Tablets
- Eye drops
- Ointments
- Others
- Gels
- Eye solutions & suspensions
- Capsules & Tablets
- Eye drops
- Ointments
Japan ophthalmic drugs route of administration outlook (Revenue, USD million, 2021-2033)
- Topical
- Systemic
- Local Ocular
- Subconjunctival
- Intravitreal
- Retrobulbar
- Intracameral
Japan ophthalmic drugs dosage type outlook (Revenue, USD million, 2021-2033)
- Gels
- Eye solutions & suspensions
- Capsules & Tablets
- Eye drops
- Ointments
Japan ophthalmic drugs product type outlook (Revenue, USD million, 2021-2033)
Japan ophthalmic drugs drug type outlook (Revenue, USD million, 2021-2033)
- Branded Drugs
- Generic Drugs